Merkoša sitáhtat
APA-čujuhus (7. p.)
Matsumoto, D., Naiki, T., Naiki‐Ito, A., Aoki, M., Kato, S., Morikawa, T., . . . Yasui, T. (2025). Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases. Wiley.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Chicago-čujuhus (17. p.)
Matsumoto, Daisuke, et al. Efficacy of Pembrolizumab Plus Lenvatinib as First‐line Treatment for Metastatic Renal Cell Carcinoma with Multiple Brain Metastases. Wiley, 2025.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
MLA-čujuhus (9. p.)
Matsumoto, Daisuke, et al. Efficacy of Pembrolizumab Plus Lenvatinib as First‐line Treatment for Metastatic Renal Cell Carcinoma with Multiple Brain Metastases. Wiley, 2025.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.